Article Text

AB0804 The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients Undergoing Dialysis
  1. D.-H. Lim1,
  2. J.S. Oh2,
  3. S.M. Ahn1,
  4. S. Hong1,
  5. W.J. Seo3,
  6. Y.-G. Kim1,
  7. C.-K. Lee1,
  8. S.W. Choi2,
  9. B. Yoo1
  1. 1Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, Univ. of Ulsan College of Medicine, Seoul
  2. 2Division of Rheumatology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea, Ulsan
  3. 3Division of Rheumatology, Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea, Republic Of


Background Febuxostat is metabolized mainly in the liver and is excreted through both urine and feces, suggesting that it may be an alternative choice for the treatment of hyperuricemia and gout in chronic kidney disease (CKD) patients. However, there are insufficient data on the use of febuxostat in patients undergoing dialysis.

Objectives The aims of our study were to investigate the efficacy and tolerability of febuxostat in hyperuricemic patients on dialysis.

Methods We retrospectively reviewed clinical and laboratory data from two tertiary referral centers from January 2012 to December 2015. We included 49 patients with underlying CKD on dialysis who started febuxostat treatment in the two hospitals.

Results The mean age of the study patients was 54.4±12.5 year and follow-up duration was 12.7±10.2 months (Table 1). Among 41 patients who were treated with febuxostat for over 3 months, the mean serum uric acid level at 3 months after treatment (4.97±1.84 mg/dL) was significantly reduced compared with the pretreatment level (9.61± 2.18 mg/dL) (p<0.001). And the serum uric acid level stayed significantly lower for 12 months without deterioration in eGFR. Of the 49 patients, only 2 stopped the medication due to adverse event. The two patients who stopped taking febuxostat were on peritoneal dialysis.

Table 1.

Baseline characteristics of the study patients at the time of febuxostat initiation

Conclusions Febuxostat is efficacious and well tolerated in hyperuricemic patients undergoing dialysis. Close observation for adverse events might be needed for patients on peritoneal dialysis.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.